Richard Finn, MD, discusses the interim results of the REFINE Study, which tests the real-world dosing of regorafenib in patients with unrespectable hepatocellular carcinoma.
Richard Finn, MD, a hematologic oncologist at the UCLA Jonsson Comprehensive Cancer Center, discusses the interim results of the REFINE Study, which tests the real-world dosing of regorafenib (Stivarga) in patients with unrespectable hepatocellular carcinoma (HCC).
According to Finn, all of the patients in the study were previously treated with sorafenib (Nexavar). Care providers either administered a full dose of regorafenib, or the dose of their choice. Some patients were administered 120 mg or as little as 80 mg of regorafenib daily. Dosing seemed to be based on the prior sorafenib dose, Finn notes.
Survival in the group was about 13 months. Adverse events were similar to those observed in the RESORCE study (NCT01774344). Additionally, according to Finn, the safety profiles was similar regardless of the dose. Dose de-escalation was also determined to be related to prior sorafenib.
Gholam Analyzes Treatment Outcomes for Advanced HCC in Child-Pugh B Population
April 28th 2024During a live Community Case Forum event in partnership with the Tennessee Oncology Practice Society, Pierre Gholam, MD, examined the current state of treatment for patients with hepatocellular carcinoma, looking in particular at what data is available for those with Child-Pugh B and C status who have poorer outcomes and have limited data from prospective clinical trials.
Read More